Entering text into the input field will update the search result below

Daxor's BVA-100 demonstrates ease of use in critically ill patients

Feb. 22, 2019 9:34 AM ETDaxor Corporation (DXR) StockBy: SA News Team
  • Daxor (NASDAQ:DXR) is up 2% in response to new research supporting the value proposition of its BVA-100 test. The results were presented at Society of Critical Care Medicine Congress in San Diego.
  • Recent studies showed 97% agreement between one (BVA-100) and five blood draws in critically ill patients and that BVA-100 was the most accurate way to establish blood volume.
  • Reducing blood sampling will result in more rapid reporting of test results with a corresponding reduction in the quantity of blood sampled, technician time and costs.
  • BVA-100 Blood Volume Analyzer, is the first instrument approved by the FDA to provide rapid direct measurement of a patient’s blood volume.

Recommended For You

More Trending News

About DXR Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
DXR--
Daxor Corporation